−4.9%
since Sep 30
The idea
I believe medicine two decades from now looks completely different: one-time gene fixes instead of lifelong treatment, AI designing drugs instead of brute-force screening, and blood tests catching cancer years early. Rather than pick a single winner, about a quarter sits in the tools and instrument makers every breakthrough depends on, with the rest spread thin across gene editing, AI drug discovery, early detection, and new care delivery.
What it owns
- The take bets that drug developers and labs will keep spending on the infrastructure needed to discover and manufacture any breakthrough, regardless of which one wins. · Thermo Fisher ScientificIt sells the instruments and supplies nearly every drug developer and research lab depends on, so it gets paid whichever therapy wins., DanaherIt supplies equipment for making biologic drugs and running diagnostics, steady infrastructure that works with any therapy that wins., West Pharmaceutical ServicesIt makes vials, stoppers, and injection components nearly every injectable drug ships in, from gene to biologic therapies., IlluminaIt makes DNA sequencers behind most genomic medicine, so cheaper and more common sequencing flows straight to it., Agilent TechnologiesIt sells measurement and analysis instruments labs use daily, another way to get paid regardless of which therapy wins., 10x GenomicsIt sells tools that let scientists study biology one cell at a time, the resolution next-generation cures get designed at.28%
- The take holds companies racing to prove that gene editing and genomic targeting can replace lifelong treatment with one-time cures. · Vertex PharmaceuticalsIt already sells Casgevy, the first approved CRISPR therapy, and proves one-time cures can be a real business with profitable drugs., CRISPR TherapeuticsIt co-owns Casgevy with Vertex and represents the bet that gene editing replaces lifelong treatment., Regeneron PharmaceuticalsIt built one of the largest human genetic databases and uses it to pick drug targets, the data-first approach this take expects to win., Beam TherapeuticsIts base editing changes single DNA letters without cutting the strand, potentially safer and more precise than first-generation CRISPR., ARK Genomic Revolution ETFIt holds dozens of genomics companies in one fund, insurance that the take can be right about the field even if individual bets go wrong., Intellia TherapeuticsIt tries to edit genes directly inside a patient's body rather than in a lab, which would open gene editing to far more diseases.27%
- The take bets that artificial intelligence will design more drugs than traditional screening, running on specialized chips and trained on real patient data. · NVIDIAIf artificial intelligence designs drugs of the future, it runs on these chips, from protein models to virtual screening., Tempus AIIt turns patient records and genomic data into training material for medical artificial intelligence, the raw ingredient drug discovery needs most., Recursion PharmaceuticalsIt runs automated labs that generate biology data at scale to train drug-finding artificial intelligence., SchrodingerIts software simulates how drug molecules behave before anyone makes them, replacing brute-force screening with computational design.16%
- The take expects constant body data and machines in the clinic to beat occasional visits and manual management. · Intuitive SurgicalIt dominates robot-assisted surgery and future care delivery almost certainly involves more machines in operating rooms, not fewer., DexComIts continuous glucose monitors prove that constant body data beats occasional doctor visits in managing disease., InsuletIts tubeless pump paired with sensors moves diabetes care from constant patient effort to automated management.13%
- The take expects blood tests and genomic screening to catch disease years before symptoms, shifting medicine toward prevention. · NateraIts blood tests detect cancer recurrence and screen pregnancies from a simple draw, the early-detection future this take counts on., Guardant HealthIt bets directly on blood tests catching cancer years earlier through screening.8%
- Cash8%